A midstage trial found that Cempra Pharmaceuticals' drug candidate solithromycin is as effective as FDA-approved antibiotic levofloxacin in treating community-acquired bacterial pneumonia, but with less risk of adverse effects. The result supports further evaluation of solithromycin in a Phase III test, said Cempra official David Oldach. The drug is also expected to work against sexually transmitted diseases and Legionnaires' disease.

Full Story:

Related Summaries